Stock 603590 BEIJING KONRUNS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Beijing Konruns Pharmaceutical Co.,Ltd. Stock

Equities

603590

CNE1000036K3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
28.3 CNY +0.64% Intraday chart for Beijing Konruns Pharmaceutical Co.,Ltd. -0.88% -25.68%
Apr. 25 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 08 Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 1.08B 149M Sales 2025 * 1.35B 187M Capitalization 4.47B 617M
Net income 2024 * 185M 25.55M Net income 2025 * 230M 31.76M EV / Sales 2024 * 4.15 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.31 x
P/E ratio 2024 *
24.2 x
P/E ratio 2025 *
19.6 x
Employees 447
Yield 2024 *
-
Yield 2025 *
-
Free-Float 45.66%
More Fundamentals * Assessed data

Chart Beijing Konruns Pharmaceutical Co.,Ltd.

Dynamic Chart

Latest news about Beijing Konruns Pharmaceutical Co.,Ltd.

Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Konruns Pharma Enrolls First Subject in Phase 3 Study of Cancer Drug MT
Beijing Konruns Pharmaceutical Gets Nod to Test KC1036 Tablets as Esophagus Cancer Treatment MT
Konruns Pharmaceutical Gets Clearance for Clinical Trial of Sarcoma Treatment MT
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023. CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd. CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd. CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2022. CI
Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction announced on March 1, 2021 CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news

Quotes and Performance

1 week-1.51%
Current month-4.94%
1 month-4.94%
3 months-8.76%
6 months-31.88%
Current year-26.16%
More quotes

Highs and lows

1 week
27.80
Extreme 27.8
28.55
1 month
27.80
Extreme 27.8
33.15
Current year
23.19
Extreme 23.19
38.23
1 year
23.19
Extreme 23.19
41.95
3 years
21.95
Extreme 21.95
41.95
5 years
21.95
Extreme 21.95
56.96
10 years
21.95
Extreme 21.95
56.96
More quotes

Managers and Directors - Beijing Konruns Pharmaceutical Co.,Ltd.

Managers TitleAgeSince
Jian Hua Liu FOU
 Founder 64 03-09-02
Xi Juan Wang FOU
 Founder 63 03-09-02
Zhan Qi Niu PSD
 President 57 23-07-19
Members of the board TitleAgeSince
Xi Juan Wang FOU
 Founder 63 03-09-02
Li Jia Fu BRD
 Director/Board Member 61 21-10-26
Jian Hua Liu FOU
 Founder 64 03-09-02
More insiders

Quotes

Date Price Change Volume
24-05-30 28.3 +0.64% 726 700
24-05-30 28.12 0.00% 519,700
24-05-29 28.12 -0.46% 454,100
24-05-28 28.25 -0.42% 549,500
24-05-27 28.37 +0.60% 756,383

End-of-day quote Shanghai S.E., May 29, 2024

More quotes

Company Profile

Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-07-29 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Beijing Konruns Pharmaceutical Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
28.12 CNY
Average target price
44 CNY
Spread / Average Target
+56.47%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. Stock Beijing Konruns Pharmaceutical Co.,Ltd.
-26.16% 617M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+39.82% 734B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.47% 591B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.31% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.23% 315B
ABBVIE INC. Stock AbbVie Inc.
+0.86% 276B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.81% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-6.54% 204B
NOVARTIS AG Stock Novartis AG
+8.32% 206B
AMGEN INC. Stock Amgen Inc.
+4.51% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603590 Stock